Q32 Bio Inc (QTTB) Actualités

Form 8-K - Current report

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 8-K - Current report

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development Program

Q32 Bio Provides Bempikibart Program Update, Including Next Steps for Advancing Alopecia Areata Development...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Q32 Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update PR Newswire WALTHAM, Mass...

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference

Q32 Bio to Participate in Guggenheim's Inaugural Healthcare Innovation Conference PR Newswire WALTHAM, Mass...

Form 4 - Statement of changes in beneficial ownership of securities

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the American Society of Nephrology Kidney Week 2024

Q32 Bio to Present Tissue-Targeted Complement Inhibitor ADX-097 Positive Phase 1 Clinical Trial Results at the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities